Welcome to DukeHealth.org.
Skip over navigation
  • Home
  • Patient and Visitor Info
  • Physicians
  • Services
  • Clinical Trials
  • Event Calendar
  • Locations
  • Health Library
  • About Duke Medicine

Quick Links

  • Appointments
  • HealthView Patient Login
  • Quality and Safety
Home > Physicians > Muir, Andrew J.
Jumbo Large Regular Text:
Print
Physicians

Andrew J. Muir, MD, MHS

Related Content

Locations

  • Duke Medicine at Brier Creek (GI Services)

Services

  • ERCP
  • Liver Disorders
  • Liver Transplant

Health Library

  • Added Anti-Viral Improves Response, Halves Duration of Hepatitis C Treatment

Share

Andrew J. Muir, MD, MHS

Clinical Director, Hepatology

Department / Division
Medicine / Medicine - Gastroenterology

Address
DUMC 3913
Durham, NC 27710

Appointment Telephone
919-684-6437

Office Telephone
919-684-2052

Fax Telephone
919-684-8264

Training
  • MD, Duke University School of Medicine, 1993

Residency
  • Internal Medicine, Duke University Medical Center, 1993-1996 (Chief Resident, 1997-1998)

Fellowship
  • Gastroenterology, Duke University Medical Center, 1996-1997, 1998-2000

Clinical Interests
General hepatology, transplant hepatology, hepatitis C, hepatocellular carcinoma

Research Interests
· Hepatitis C
· Liver Transplantation
· Hepatocellular carcinoma
· Clinical Trials
· Racial disparities in liver disease
· Outcomes Research

Industry Relationships and Collaborations (What's this?)

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

  • Abbott Laboratories
  • Achillion Pharmaceuticals
  • Bristol-Myers Squibb
  • Cook Medical
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • GlobeImmune, Inc.
  • Janssen Pharmaceuticals (Johnson & Johnson)
  • Merck
  • Novartis
  • Pfizer Inc.
  • Profectus
  • Roche
  • Salix Pharmaceuticals, Ltd.
  • Vertex Pharmaceuticals Inc.

Representative Publications
Muir, AJ. The protease inhibitor era: an opportunity to improve the quality of care. Digestive Diseases and Sciences. 2011;56:1252-1254. (2011) Abstract

Muir, AJ; Hu, KQ; Gordon, SC; Koury, K; Boparai, N; Noviello, S; Albrecht, JK; Sulkowski, MS; McCone, J. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. Journal of Viral Hepatitis. 2011;18:e134-e143. (2011) Abstract

Muir, AJ; Poordad, FF; McHutchison, JG; Shiffman, ML; Berg, T; Ferenci, P; Heathcote, EJ; Pawlotsky, JM; Zeuzem, S; Reesink, HW; Dusheiko, G; Martin, EC; George, S; Kauffman, RS; Adda, N. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011;54:1538-1546. (2011) Abstract

Jou, JH; Chen, PH; Jazwinski, A; Bouneva, I; Smith, AD; Muir, AJ. Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center. Digestive Diseases and Sciences. 2010;55:3591-3596. (2010) Abstract

McHutchison, JG; Manns, MP; Muir, AJ; Terrault, NA; Jacobson, IM; Afdhal, NH; Heathcote, EJ; Zeuzem, S; Reesink, HW; Garg, J; Bsharat, M; George, S; Kauffman, RS; Adda, N; Di Bisceglie, AM; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. New England Journal of Medicine. 2010;362:1292-1303. (2010) Abstract

Muir, AJ; Shiffman, ML; Zaman, A; Yoffe, B; de la Torre, A; Flamm, S; Gordon, SC; Marotta, P; Vierling, JM; Lopez-Talavera, JC; Byrnes-Blake, K; Fontana, D; Freeman, J; Gray, T; Hausman, D; Hunder, NN; Lawitz, E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010;52:822-832. (2010) Abstract

Ge, D; Fellay, J; Thompson, AJ; Simon, JS; Shianna, KV; Urban, TJ; Heinzen, EL; Qiu, P; Bertelsen, AH; Muir, AJ; Sulkowski, M; McHutchison, JG; Goldstein, DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401. (2009) Abstract

McHutchison, JG; Everson, GT; Gordon, SC; Jacobson, IM; Sulkowski, M; Kauffman, R; McNair, L; Alam, J; Muir, AJ; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New England Journal of Medicine. 2009;360:1827-1838. (2009) Abstract

McHutchison, JG; Lawitz, EJ; Shiffman, ML; Muir, AJ; Galler, GW; McCone, J; Nyberg, LM; Lee, WM; Ghalib, RH; Schiff, ER; Galati, JS; Bacon, BR; Davis, MN; Mukhopadhyay, P; Koury, K; Noviello, S; Pedicone, LD; Brass, CA; Albrecht, JK; Sulkowski, MS; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine. 2009;361:580-593. (2009) Abstract

Brady, CW; Smith, AD; Stechuchak, KM; Coffman, CJ; Tuttle-Newhall, JE; Provenzale, D; Muir, AJ. Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era. Liver Transplantation. 2008;14:228-234. (2008) Abstract

Jou, JH; Muir, AJ. In the clinic. Hepatitis C. Annals of Internal Medicine. 2008;148:ITC6-1-ITC6-16. (2008) Abstract

Lawitz, E; Rodriguez-Torres, M; Muir, AJ; Kieffer, TL; McNair, L; Khunvichai, A; McHutchison, JG. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. Journal of Hepatology. 2008;49:163-169. (2008) Abstract

Patel, K; Muir, AJ; McHutchison, JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ. 2006;332:1013-1017. (2006) Abstract

Ramamurthy, M; Muir, AJ. Treatment of hepatitis C in special populations. Clinics in Liver Disease. 2006;10:851-865. (2006) Abstract

Condron, SL; Heneghan, MA; Patel, K; Dev, A; McHutchison, JG; Muir, AJ. Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. Transplantation. 2005;80:145-148. (2005) Abstract

Muir, AJ; Bornstein, JD; Killenberg, PG; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. New England Journal of Medicine. 2004;350:2265-2271. (2004) Abstract

Contact Us | Careers | Privacy Policy | Make a Gift | Site Map | RSS Feeds | En Español | Mobile Site | Help
Duke Medicine | Duke School of Medicine | Duke Children's | Duke University
Toll-Free: 888-ASK-DUKE (888-275-3853)
Copyright © 2004-2013 Duke University Health System

About This Page

Updated: Nov. 5, 2010
Published: Dec. 12, 2006
URL: http://www.dukehealth.org/physicians/andrew_j_muir